Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
New leaders in regulatory affairs and manufacturing at Pharnext SA and promotions at Abeona Therapeutics are among recent executive changes in the industry. Meanwhile, new directors were appointed at Onxeo SA, Avalo Therapeutics and Spero Therapeutics, among others.
The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.
Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.
New leaders in regulatory affairs and R&D at Skye Bioscience and promotions at Pieris Pharmaceuticals are among recent executive changes in the industry. Meanwhile, new directors were appointed at Summit Therapeutics, Ovid Therapeutics and Spero Therapeutics, among others.
The company created two new divisions focused on the new disease areas, bringing in former executives from Bristol Myers Squibb and Sanofi Pasteur.
Chief scientific officer Paul Stoffels will retire at the end of the year at the same time CEO Alex Gorsky will hand over the top leadership role to Joaquin Duato; no successor has been named.
Richard Pulik joins Roivant from Novartis, Hamish George joins Amplia from Dimerix, and Khiron, Immunovant, Quiapeg Pharmaceuticals and Vascular Biogenics also get new CFOs.
Hyloris picks up new chief financial officer, new chief medical officer joins Cyclo and more.
Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO
, and has underlined competitive threats to a key pipeline candidate.
"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke with Scrip about competitive rebating and new growth opportunities for anchor brands.
New CEOs at Mirati Therapeutics Nordic Nanovector, Rappta Therapeutics and more.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.